Galapagos NV
GLPG | BR
Overview
Corporate Details
- ISIN(s):
- BE0003818359
- LEI:
- 549300QKJ78IY0IOV655
- Country:
- Belgium
- Address:
- Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
- Website:
- https://www.glpg.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-23 08:37 |
Board/Management Change
Galapagos benoemt Aaron Cox als Chief Financial Officer
|
Dutch | 280.5 KB | |
| 2025-06-23 08:37 |
Board/Management Change
Galapagos benoemt Aaron Cox als Chief Financial Officer
|
English | 268.4 KB | |
| 2025-06-23 07:30 |
Board/Management Change
Galapagos Press Release_CFO_ENG.pdf
|
English | 268.4 KB | |
| 2025-06-23 07:30 |
Board/Management Change
Galapagos Press Release_CFO_NL.pdf
|
Dutch | 280.5 KB | |
| 2025-06-19 07:38 |
Earnings Release
Company announcement
|
Dutch | 347.4 KB | |
| 2025-06-19 07:38 |
Earnings Release
Company announcement
|
English | 314.4 KB | |
| 2025-06-13 07:36 |
Inside Information Statement
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low To…
|
Dutch | 361.6 KB | |
| 2025-06-13 07:36 |
Inside Information Statement
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low To…
|
English | 328.8 KB | |
| 2025-05-28 07:32 |
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
|
Dutch | 218.9 KB | |
| 2025-05-28 07:32 |
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
|
English | 211.4 KB | |
| 2025-05-27 22:30 |
Share Issue/Capital Change
Subscription-Right-Plan-2025-A-Board-Report_English_Final_Website.pdf
|
English | 218.0 KB | |
| 2025-05-27 22:30 |
Share Issue/Capital Change
Subscription-Right-Plan-2025-A-Board-Report_Dutch_Final_Website.pdf
|
Dutch | 249.5 KB | |
| 2025-05-13 07:30 |
Regulatory News Service
GLPG Press-release Strategic Review May 2025 ENG.pdf
|
English | 275.9 KB | |
| 2025-05-13 07:30 |
Regulatory News Service
GLPG Press Release Strategic Review May 2025_NL.pdf
|
Dutch | 302.9 KB | |
| 2025-04-24 06:28 |
Earnings Release
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlig…
|
Dutch | 603.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Guenter Peter | Board | Buy | 925 | 24,603.46 EUR |
| 2025-01-10 | Svanberg Elisabeth | Board | Buy | 915 | 24,348.15 EUR |
| 2024-07-03 | Huston Thad | Board | Buy | 50,000 | N/A |
| 2024-05-17 | Stoffels IMC | Board | Buy | 75,000 | N/A |
| 2024-05-01 | Stoffels IMC | Board | Other | 50,921 | 1,428,334.05 EUR |
| 2024-05-01 | Missotten Annelies | Board | Other | 13,333 | 373,990.65 EUR |
| 2024-05-01 | Cnossen Valeria | Board | Other | 13,151 | 368,885.55 EUR |
| 2024-05-01 | Huston Thad | Board | Other | 12,636 | 354,439.80 EUR |
| 2024-04-30 | GILEAD THERAPEUTICS A1 UNLIMITED COMPANY | Close relation | Other | 1 | N/A |
| 2023-12-21 | Guenter Peter | Board | Buy | 644 | 23,069.75 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |